PCI Pharma Services to build Clinical Supply Centre of Excellence in New England
The first-of-its-kind centre will offer biopharma clients convenience and efficiencies in the rapidly expanding Northeast
To meet the growing clinical supply market demands in New England, PCI Pharma Services has announced it is constructing a new Clinical Centre of Excellence in Bridgewater, Massachusetts.
This investment makes the company the first global CDMO with integrated end-to-end capabilities to build such a centre, which will provide clinical storage, distribution and packaging with a strong focus on cold chain capabilities.
The company says the new 50,000-sq. ft centre will allow it to be closer to clients in the tri-state area and engage with more than 1000 Boston/Cambridge, the nation’s top biopharma cluster.
Brian Keesee, Vice President and General Manager, Global Operations and Supply of Clinical Services, PCI Pharma Services said the centre will also offer biopharmaceutical clients more convenience and efficiencies, as well as combining a "local feel and global capabilities".
“This expansion is part of our larger strategy to serve biopharmaceutical clients by providing a facility that can service their needs within a relatively short driving distance, while adding to our global footprint," added Keesee.
This news comes less than a month after PCI Pharma announced it is acquiring Lyophilization Services New England, a premier CDMO headquartered in Bedford, New Hampshire.
During the last 18 months, PCI has invested significantly in its global clinical sites including San Diego, Rockford, Melbourne and Berlin as part of its global clinical expansion in all services, including investing in new facilities, refrigerators and freezers, increasing capacity, and adding new storage conditions in service to both large and small molecule compounds.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...